GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5131 [(pF)Phe4]Nociceptin(1-13)NH2Summary: nociceptin/orphanin FQ receptor (OP4) agonist peptide -
B5136 [Arg14,Lys15]NociceptinSummary: Highly potent and selective NOP receptor agonist -
B5145 Urocortin (human)Summary: Endogenous CRF agonist -
B5146 Urocortin (rat)Summary: Endogenous CRF agonist -
B5147 AstressinSummary: corticotropin-releasing factor (CRF) receptor antagonist -
B5148 CRF (6-33)Summary: Corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide -
B5149 Stressin ISummary: corticotropin releasing factor receptor-1 (CRF1) agonist -
B5150 SauvagineSummary: Corticotropin-releasing factor (CRF) receptor agonist -
B5154 Urotensin II (human)Summary: Potent endogenous peptide agonist for the urotensin-II receptor -
B5156 O-2050Summary: high affinity cannabinoid CB1 receptor silent antagonist

